AstraZeneca to buy Alexion for $39 billion to expand in immunology

AstraZeneca to buy Alexion for $39 billion to expand in immunology Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in cash and shares to bolster its positions in immunology and rare diseases. https://ift.tt/3qRCabi https://ift.tt/3bCaRe2 Markets December 12, 2020 at 07:51PM